UnknownNot Applicable

Identification of Novel Inflammation-related Biomarkers for Early Detection of Anthracycline-induced Cardiotoxicity in Breast Cancer Patients

180 participantsStarted 2022-04

Plain-language summary

This study aims to identify possible set of inflammatory biomarkers before, during and after anthracycline-based chemotherapy in breast cancer patients to identify (sub)clinical chemotherapy-related cardiac dysfunctionCRCD to identify patients who would benefit from additional cardioprotective therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * initial diagnosis of breast cancer * planned Anthracycline-based therapy * first-line chemotherapy * first visit before initiation of chemotherapy Exclusion Criteria: * previous chemotherapy * medical history of cardiac disease * inflammation-modulating medication * medication with RAS inhibitors * pregnancy * autoimmune disease * drug addictions * unwilling or unable to provide informed consent

What they're measuring

Cardiotoxicity during observational period

Timeframe: continuous evaluation during observational period of 12 months

Trial details

NCT IDNCT05298072

SponsorUniversity Hospital, Essen

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-04

View on ClinicalTrials.gov More Cardiotoxicity trials